Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism

Basit Öğe Kaydı
dc.contributor.authorTaskapu, Hakan Hakki
dc.contributor.authorSonmez, Mehmet Giray
dc.contributor.authorKilinc, Muzaffer Tansel
dc.contributor.authorAltinkaya, Nurullah
dc.contributor.authorAydin, Arif
dc.contributor.authorBalasar, Mehmet
dc.date.accessioned2024-02-23T14:24:01Z
dc.date.available2024-02-23T14:24:01Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractIn this study, the efficiency of intracavernosal alprostadil + oral clomiphene citrate (CC) treatment in late-onset hypogonadism (LOH) accompanied by penile vasculogenic erectile dysfunction (PVED) in patients irresponsive to phosphodiesterase type 5 inhibitor treatment was evaluated. A total of 31 patients with concurrent PVED and LOH were included in the study. The patients were given intracavernosal alprostadil (10-20 mu g) and oral CC (50 mg) every day for 12 weeks. Before and after treatment, a 15-question International Index of Erectile Function (IIEF-15) questionnaire, Erection Hardness Score (EHS), Sexual Encounter Profile (SEP)2 and SEP3 levels were analysed, and follicle stimulating hormone (FSH), luteinising hormone (LH), total testosterone and prostate-specific antigen (PSA) levels were measured. In all, 41.9% of patients had pure arterial deficiency, 19.3% had pure venous deficiency, and 38.7% had arterial + venous (mixed) deficiency. A significant increase was detected in total testosterone, FSH, LH and PSA values after treatment when compared to values before treatment (p < .001,p < .001,p p = .034 respectively). A significant recovery was observed in IIEF-15 subscores, EHS and SEP2-SEP3 results. In PVED patients accompanied by LOH, intracavernosal alprostadil and oral CC combination is an efficient, low cost, safely applicable and tolerable treatment.en_US
dc.identifier.doi10.1111/and.13759
dc.identifier.issn0303-4569
dc.identifier.issn1439-0272
dc.identifier.issue10en_US
dc.identifier.pmid33617097en_US
dc.identifier.scopus2-s2.0-85088270816en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/and.13759
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13783
dc.identifier.volume52en_US
dc.identifier.wosWOS:000550564200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAndrologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAlprostadilen_US
dc.subjectClomiphene Citrateen_US
dc.subjectErectile Dysfunctionen_US
dc.subjectHypogonadismen_US
dc.subjectIntracavernosal Treatmenten_US
dc.titleEfficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu